Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of New Era Energy & Digital, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased New Era Energy & Digital securities may be entitled to compensation through a class action without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the alleged misleading information [2]. Group 2: Stock Performance and Allegations - On December 12, 2025, New Era Energy & Digital's stock fell by 6.9% following a report from Fuzzy Panda Research, which accused the company of spending 2.5 times more on stock promotions than on operating its oil and gas wells [3]. - The report also highlighted the CEO's history of mismanagement in penny stock companies over approximately 20 years [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 5, 2026 [3]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary launch steps, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

Core Viewpoint - A class action has been filed against Gauzy Ltd. for allegedly misleading investors about its financial stability and business prospects during a specified period [1][2]. Group 1: Allegations and Financial Issues - The complaint alleges that Gauzy failed to disclose that three of its French subsidiaries were unable to meet their financial obligations, leading to a substantial likelihood of insolvency proceedings [2]. - The company announced on November 14, 2025, that the Commercial Court of Lyon ordered the commencement of insolvency proceedings for these subsidiaries, which constitutes a default under its existing senior secured debt facilities [3]. - Following the announcement of insolvency proceedings, Gauzy's share price dropped by $2.00, or 49.8%, closing at $2.02 per share on November 17, 2025 [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers by February 6, 2026, although participation is not required to be eligible for recovery [4]. - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Klarna Group plc due to allegations of materially misleading business information issued by Klarna [1]. Group 1: Investigation Details - The investigation is prompted by a Yahoo! Finance article that reported Klarna's record revenue for Q3, but also highlighted a net loss of $95 million and increased provisions for credit losses [3]. - Provisions for loan losses were reported at $235 million, exceeding analyst estimates of $215.8 million, and represented 0.72% of gross merchandise volume, up from 0.44% the previous year [3]. - Following the news, Klarna's stock experienced a decline of 9.3% on November 18, 2025 [3]. Group 2: Class Action Information - Investors who purchased Klarna securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the Rosen Law Firm directly [2]. Group 3: Rosen Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest ever against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability and success in this area [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the allegations against Tandem Diabetes [2]. Group 2: Company Incident - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Alvotech on November 2, 2025, which announced that the U.S. FDA issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, indicating deficiencies that must be resolved before approval [3]. - Following the announcement of the CRL, Alvotech's stock price experienced a significant decline, falling 34% on November 3, 2025, and nearly 4% on November 4, 2025 [3]. Group 2: Class Action Information - Shareholders who purchased Alvotech securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested investors can join the prospective class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the December 15, 2025 deadline for a securities class action [1]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions, highlighting their own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its success in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of MoonLake's Nanobodies compared to traditional monoclonal antibodies, leading to investor losses when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that during the class period, the defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors over the years [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is focused on claims that Tandem Diabetes Care may have misled investors regarding its business practices [1]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses, allowing affected shareholders to join without upfront costs [2]. Group 2: Incident Overview - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Alvotech on November 2, 2025, which announced that the U.S. FDA issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, indicating deficiencies that must be resolved before approval [3]. - Following the announcement of the CRL, Alvotech's stock price experienced a significant decline, falling 34% on November 3, 2025, and nearly 4% on November 4, 2025 [3]. Group 2: Class Action Information - Shareholders who purchased Alvotech securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested investors can join the prospective class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has received recognition for its attorneys in the legal field [4].